Novo Nordisk, a leading pharmaceutical company, has announced that it will be retaining its popular insulin brand, Mixtard, in vial format in the Indian market, despite discontinuing Penfill cartridges. This strategic move comes in response to apprehensions regarding the phasing out of commonly used insulin products. By streamlining its insulin offerings, Novo Nordisk aims to cater to the rising need for insulin among patients while also guaranteeing a consistent supply of medication. The company’s decision to concentrate on newer treatments reflects its commitment to providing advanced healthcare solutions. Novo Nordisk’s dedication to ensuring the availability of Mixtard in vial form underscores its efforts to support individuals in managing diabetes effectively.